With healthy balance sheets and cash to deploy to expand access to innovation, corporate venture arms are becoming an increasingly sizable portion of the venture capital world. While the technology sector has been highly visible with active venture arms such as Google Ventures and Intel Capital, health-related corporate venture has been stepping up its presence in biotech over the past several years and is expected to increasingly invest in diagnostic startups in the coming years. Corporate venture capital stepped into the life sciences to fill a void left a few years ago as traditional venture capital firms began to shy away from early-stage startups. In a report titled “Strong Momentum in Healthcare: Trends in Mergers and Acquisitions Dollars,” Silicon Valley Bank (SVB) highlights this void. Dating back to 2002, venture-backed device and biotech companies represent about a quarter of all venture dollars invested on a yearly basis. However, the report explains that that pace of investment (roughly $6.6 billion a year) is not sustainable given both the decline in venture capital fund-raising overall and a potential decline in the percentage of total venture dollars allocated to the health care sector. “We believe that dollars invested into health care venture-backed companies […]